Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.
Xu L, Shadman M, Flinn IW, Levy MY, Porter R, Burke JM, Zafar SF, Cultrera JL, Misleh J, Kingsley EC, Yimer HA, Freeman B, Chaudhry A, Tumula PK, Gandhi MD, Crescenzo R, By K, Cohen A, Chen DY, Idoine A, Manda S, Sharman JP, Ramakrishnan V.
Xu L, et al.
Haematologica. 2024 Jul 1;109(7):2284-2289. doi: 10.3324/haematol.2023.283861.
Haematologica. 2024.
PMID: 38268449
Free PMC article.
Clinical Trial.
No abstract available.